- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01392248
Prediction of Pain After Breast Cancer Surgery With EEG
EEG as a Predictor for Postoperative Pain and the Development of Chronic Postsurgical Pain After Breast Cancer Surgery
- Rationale The inter-individual pain experience immediately after surgery is considerable. In addition, a number of patients develop chronic post surgery pain (CPSP). Patients undergoing surgery for breast cancer are at risk of developing both acute post surgical pain as well as CPSP. Recently, in a group of patients with chronic back pain, it was demonstrated how subjectively reported pain is associated with specific electroencephalography (EEG) parameters, namely the N2 and P3 components of the pain event-related potential (ERP). It was concluded that ERP was associated with self-reported pain in daily life up to two weeks after the measurement. This resulted in the current hypothesis that EEG may be a predictor for postoperative pain.
Study design Prospective cohort study. Within 2 weeks before surgery, 150 patients will undergo an EEG measurement with five 'vulnerability' tasks. The experiment will be repeated 6 months postoperatively.
Study population: Female patients with breast cancer who will undergo breast surgery, between the ages of 18 to 65 years.
- Main study parameters/endpoints Primary outcome is postoperative pain, measured in a pain diary 4 days postoperatively. Secondary outcomes are development of chronic post surgery pain and quality of life. The main goal is to develop a comprehensive prediction model for acute and chronic postoperative pain after breast cancer surgery, based on the EEG results of the five vulnerability experiments.
Studieoversikt
Status
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Limburg
-
Maastricht, Limburg, Nederland, 6200 MD
- Maastricht UMC
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Age 18 - 65 years.
- ASA 1-2.
- Sufficient comprehension of the Dutch spoken and written language.
- Elective curative breast cancer surgery, both mastectomy and breast- conserving therapy
- Stage I and II breast cancer.
- Written informed consent is obtained
Exclusion Criteria:
- Previous breast surgery, both ipsilateral and contralateral.
- Stage III-IV breast cancer.
- Chronic pain (>3months) with an average severity of at least a VAS score 4 during the last two weeks.
- Chronic pain for which invasive treatment is needed.
- Use of (weak / strong) opioids in the last week.
- A history of opioid addiction.
- Regular use of the following medications in the last year:
antiepileptics,antipsychotics and anxiolytics.
- ASA 3 or higher.
- Consumption of alcohol (>4 units) and / or drugs the evening before.
- Alcohol consumption (>= 5 units/day).
- Illiteracy, problems with self expression, language barrier.
- Serious vision and / or hearing problems, interfering the performance of the experimental tasks.
- A history of psychiatric complaints and/or epilepsy .
- A medical history of CVA or TIA.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Acute postoperative pain
Tidsramme: during 4 days after surgery
|
VAS measured in a daily pain diary
|
during 4 days after surgery
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Quality of Life
Tidsramme: within 2 weeks before surgery and at 3,6 and 12 months postoperatively
|
Quality of Life measured with SF-36
|
within 2 weeks before surgery and at 3,6 and 12 months postoperatively
|
Development of chronic pain
Tidsramme: at 3,6 and 12 months postoperatively
|
Brief Pain Inventory
|
at 3,6 and 12 months postoperatively
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: M. A Marcus, Prof. Dr., Maastricht University Medical Center
- Hovedetterforsker: J. van Os, Prof. Dr., Maastricht University Medical Center
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- NL34275.068.11 / MEC 11-2-006
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Brystkreft
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbeidspartnereFullførtThe Clinical Application Guide of Conebeam Breast CTKina
-
Novartis PharmaceuticalsFullførtMetastatisk brystkreft (MBC) | Locally Advance Breast Cancer (LABC)Storbritannia, Spania
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
-
Emory UniversityNational Cancer Institute (NCI)TilbaketrukketPrognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i hjernen | Metastatisk brystkarsinom | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnatomisk stadium IV brystkreft AJCC v8 | Prognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i beinet | Metastatisk malign neoplasma i lymfeknutene | Metastatisk malign neoplasma i leveren | Metastatisk brystkarsinom | Metastatisk malign neoplasma i lungen | Metastatisk malign neoplasma... og andre forholdForente stater, Canada, Saudi-Arabia, Korea, Republikken